RESUMEN
Objective@#To explore effects of histone deacetylase inhibitor Belinostat on the immunologic function of dendritic cells (DC) and its possible mechanism.@*Methods@#Cultured mouse bone marrow-derived DC from C57BL/6 mouse in vitro. The experiments were divided into 0, 50, 100 nmol/L Belinostat + immature DC (imDC) group, and 0, 50, 100 nmol/L Belinostat mature DC (mDC). The changes of the ultrastructure of DC were observed by transmission electron microscope (TEM). Immunophenotype and CCR7 expression rate were detected by FCM, and the migration rate was observed by chemotaxis assay. The proliferation of lymphocytes stimulated by different DC was detected by mixed lymphocyte culture reaction. The cytokines in the culture supernatant, including TNF-α, IL-12 and IL-10, were examined by ELISA. RQ-PCR was used to examine the relative expression of mRNA in RelB.@*Results@#Successful cultured and identified the qualified imDC and mDC. Belinostat decreased the expression of CCR7 on imDC [(25.82±7.25)% vs (50.44±5.61)% and (18.71±2.00)% vs (50.44±5.61)%], meanwhile increased the rate on mDC [(71.14±1.96)% vs (64.90±1.47)%]. Chemotaxis assay showed that the migration rate of Belinostat+imDC and Belinostat+mDC group were both decreased, but the difference in imDC was not significant. T lymphocyte proliferation rate stimulated by 100 nmol/L Belinostat+imDC group was lower than imDC group in condition irritation cell∶reaction cell=1∶2 [(227.09±13.49)% vs (309.49±53.69)%]. Belinostat significantly suppressed the secretion of cytokines TNF-α, IL-12 and IL-10 (all P<0.01). The relative expression of mRNA in RelB was slightly decreased in Belinostat+imDC and Belinostat+mDC group (all P<0.05).@*Conclusion@#Belinostat could effectly suppress DC maturation and regulate immune tolerance of DC, which may be due to the down-regulation of mRNA level of RelB in DC.
RESUMEN
OBJECTIVE:To investigate clinical efficacy and safety of Fluticasone furoate nasal spray in the treatment of aller-gic rhinitis(AR). METHODS:100 AR patients in our hospital during Jan. 2014-Dec. 2015 were divided into control group and ob-servation group according to random number table,with 50 cases in each group. Both groups received decongestant Oxymetazoline hydrochloride spray. Control group was additionally given Budesonide spray,once each nostril on the first day,twice each nostril on the second day,increasing suitably according to disease condition,less than 6 times a day for patients younger than 14 years old,less than 8 times a day for patients older than 14 years old;observation group was additionally given Fluticasone furoate nasal spray,once each nostril,qd for patients younger than 14 years old,once each nostril,while morning and night for patients older than 14 years old. Both groups received treatment for consecutive 30 d. The total nasal symptoms score(TNSS),total eye symp-toms score (TESS),total nasal resistance (TNR) under 75,150 Pa,nasal minimum cross-sectional area (MCA) and the occur-rence of ADR were compared between 2 groups before and after treatment. RESULTS:There was no statistical significance in above indexes between 2 groups before treatment (P>0.05). After treatment,TNSS of 2 groups and TESS of observation group were decreased significantly compared to before treatment,and TESS of observation group was significantly lower than that of con-trol group,with statistical significance (P0.05). TNR of 2 groups under 75,150 Pa were significantly lower than before treatment,and the observation group was lower than the control group,with statistical significance (P0.05). The incidence of ADR in observation group was significant-ly lower than control group,with statistical significance(P<0.05). CONCLUSIONS:Fluticasone furoate is similar to budesonide in the treatment of nasal symptoms of AR patients,but it is better than budesonide in improving eye symptoms and nasal ventila-tion function with milder ADR.